论文部分内容阅读
宋礼华,第十届、十一届、十二届全国人大代表,国家有突出贡献中青年专家(享受国务院特殊津贴),安徽安科生物工程(集团)股份有限公司董事长。人体干扰素是国际公认的治疗乙肝、丙肝的首选药物,它的生产过程中的一项关键技术是单抗的生产。单抗可以将原液中干扰素的纯度提升至95%以上,从而生产出可以临床应用的人体干扰素。打破国外公司垄断、在我国首先研制出可用于干扰素工业化生产单抗的正是本文的主人公——全国人大代表、安徽安科生物工程(集团)股份有限公司董事长宋礼华和他的
Song Lihua, the Tenth, Eleventh and Twelfth National People’s Congress, the country has made outstanding contributions to young and middle-aged experts (enjoy the State Council special allowance), Anhui Anke Bioengineering (Group) Co., Ltd. chairman. Human interferon is an internationally recognized drug of choice for the treatment of hepatitis B and hepatitis C. A key technology in its production process is the production of monoclonal antibodies. The monoclonal antibody raised the purity of the interferon in the stock solution to more than 95% to produce human interferon for clinical use. To break the monopoly of foreign companies, we first developed the monoclonal antibody that can be used for industrialized production of interferon in our country. It is the protagonist of this article - Song Lihua, chairman of Anhui Anke Bioengineering (Group) Co., Ltd. and his